Relmada Therapeutics (RLMD) Interest Coverage Ratio Growth (3y) (2017 - 2026)
Relmada Therapeutics (RLMD) Interest Coverage Ratio Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -42.41% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 28.11% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -6.89% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 79.27% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 29.47% |
| 10 | Relmada Therapeutics | 205.29 Mn | 205.29 Mn | - | 90.97% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 90.97% |
| Dec 31, 2025 | -105.88% |
| Dec 31, 2024 | -1,142.32% |
| Mar 31, 2024 | 86.02% |
| Sep 30, 2023 | 62.94% |
| Jun 30, 2023 | -27.52% |
| Mar 31, 2023 | 17.43% |
| Dec 31, 2022 | 51.39% |
| Dec 31, 2021 | -26.00% |
| Mar 31, 2021 | 49.05% |
| Sep 30, 2020 | -186.88% |
| Mar 31, 2020 | 38.74% |
| Dec 31, 2019 | -30.43% |
| Sep 30, 2019 | -35.33% |
| Jun 30, 2019 | 40.12% |
| Mar 31, 2019 | -326.60% |
| Dec 31, 2018 | 246.07% |
| Sep 30, 2018 | 17.25% |
| Mar 31, 2018 | 51.41% |
| Dec 31, 2017 | -31.07% |